FFO
EGRX

Fortitude Family Office’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Fortitude Family Office’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-117
Closed -$613 – 1071
2024
Q1 		$613 Buy
+117
New +$642 ﹤0.01% 925

Other funds holding EGRX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fortitude Family Office's EGRX Position: Q2 2024 in Review

Fortitude Family Office sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2024, closing a stake of 117 shares — an estimated $613 sold.

Fortitude Family Office first reported a position in EGRX in Q1 2024 and held it in 1 quarter. The position peaked at $613 in Q1 2024. 75 funds tracked by Wall St. Rank hold EGRX as of Q2 2024.

  • Fortitude Family Office reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • Fortitude Family Office sold 117 Eagle Pharmaceuticals, Inc. shares in Q2 2024, an estimated $613.
  • Fortitude Family Office first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2024 and held it in 1 quarter.
  • Fortitude Family Office's Eagle Pharmaceuticals, Inc. position peaked at $613 in Q1 2024.
  • 75 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2024.

Based on Fortitude Family Office's 13F filing for Q2 2024, filed 10 Jul 2024.